Ingersoll Rand (IR) Q4 2025 earnings review
Organic Growth Returns, but Tariffs Weigh on Core Margins
Ingersoll Rand finally broke a three-quarter streak of organic revenue declines, posting +2.9% organic growth in Q4. However, the victory lap is complicated by a margin divergence: while the smaller P&ST segment surged, the core Industrial (IT&S) segment saw margins compress by 140 basis points due to tariffs and growth investments. Management's FY26 guidance suggests a cautious outlook, forecasting organic growth of only 'flat to 2%', implying the Q4 momentum might not fully sustain against macro headwinds.
🐂 Bull Case
After contracting for the first three quarters of 2025 (-3.9%, -3.4%, -1.3%), organic revenue flipped to positive (+2.9%) in Q4. This validates management's narrative that the cycle is turning.
Precision & Science Technologies (P&ST) delivered stellar execution, expanding Adjusted EBITDA margins by 280 basis points to 30.4%, proving the 'Execution Excellence' (IRX) model works even in complex segments.
🐻 Bear Case
The Industrial Technologies & Services (IT&S) segment, representing ~80% of revenue, saw Adjusted EBITDA margins fall 140 basis points to 28.9%. Management explicitly blamed tariff impacts—a headwind that isn't going away in 2026.
Despite Q4's 2.9% organic growth, FY26 guidance calls for 'flat to 2%' organic growth. This signals a deceleration from current levels and suggests management lacks confidence in sustained demand recovery.
⚖️ Verdict: ⚪
Neutral. The return to organic growth is a major milestone, but the quality of earnings in the core industrial segment is deteriorating due to tariff costs. The tepid FY26 organic guidance (1% midpoint) prevents a more bullish rating.
Key Themes
Industrial Segment Margin Erosion
IT&S is the profit engine of the company, but it is sputtering. Adjusted EBITDA margin dropped 140 bps YoY to 28.9%. This continues a worrying trend (margins were down 170 bps in Q3 and 110 bps in Q2). Management cites 'dilutive impact of tariffs' and commercial investments. Pricing power appears insufficient to fully offset these headwinds immediately.
M&A Remaining a Key Growth Pillar
Inorganic growth contributed 4.4% to top-line growth in Q4, outpacing organic contribution. The company deployed $65 million in Q4 and acquired Scinomix in Jan 2026. M&A remains essential to the thesis, adding 1.5% to the 2026 growth outlook.
P&ST Segment Execution
Precision and Science Technologies turned a corner. Revenue grew 8% (4% organic), but the real story is profitability. Segment EBITDA grew 19% YoY, driven by a massive 280 bps margin expansion. This suggests operational improvements and mix shifts are finally paying off after a softer H1 2025.
Tariff Costs Persist
Tariffs were explicitly cited as a driver for IT&S margin compression in Q4. With 2026 guidance showing only modest EBITDA growth (+2-5%) relative to revenue, margin expansion appears capped by these persistent geopolitical costs.
Cash Flow Conversion
Free Cash Flow remains robust at $462M in Q4. For FY26, management guides to ~95% FCF to Adjusted Net Income conversion. This liquidity ($3.8B available) supports the buyback and M&A thesis.
Other KPIs
Accelerating. Up 11% reported and +3% organic. This is a significant improvement from the -2.1% organic decline in Q3 and -4% in Q2.
Decelerating margin. While absolute dollars grew 9%, the margin contracted 30 basis points YoY to 27.7%, dragged down by the Industrial segment.
Stable. Up 8% reported. Organic orders grew 1.1% (total company), consistent with the steady demand environment but lacking an explosive recovery signal.
Guidance
Decelerating. The midpoint (3.5%) is significantly below the Q4 exit rate of 10% reported growth. Includes +1.5% from M&A and +1% from FX.
Decelerating. The midpoint (1%) is below the Q4 result of 2.9%, suggesting management expects the macro environment to remain challenging or Q4 to be an anomaly.
Stable. Midpoint ($3.51) represents ~5% growth over FY25 ($3.34). This aligns with the revenue growth, implying limited share buyback impact or margin expansion leverage.
Stable. Represents 2-5% growth. Given revenue growth is guided at 2.5-4.5%, this implies flat EBITDA margins for FY26, likely due to the aforementioned tariff headwinds.
Key Questions
IT&S Margin Compression
IT&S margins have contracted YoY for three consecutive quarters (-110bps, -170bps, -140bps). When do you expect price/cost to neutralize the tariff impact and allow margins to expand again?
Conservative Organic Guide
You achieved 2.9% organic growth in Q4. Why guide FY26 organic growth to 'flat to 2%'? Are you seeing order deceleration in Q1 2026, or is this purely conservatism?
M&A Pipeline vs Rates
With the balance sheet leverage at 1.7x and substantial liquidity, how does the M&A pipeline look for 2026 given the current rate environment? Are valuations becoming more attractive?